Therefore, we concluded that treating cancer cells with METTL13 reinstates the G1/S checkpoint via the coordinated downregulation of CDK6, CDK4 and CCND1, which resulted in the decreased phosphorylation of Rb and consequently delayed cell cycle progression. Here, METTL13 is linked to cancer.